Status:
Enrolling
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Phase
III
Age
16-80
Sponsor
Hoffmann-La Roche
Enrollment code
600
Last Updated
Jun 22, 2025
Locations
114 Countries